Hydroxymethylglutaryl-CoA Reductase Inhibitors

"Hydroxymethylglutaryl-CoA Reductase Inhibitors" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

Compounds that inhibit HMG-CoA reductases. They have been shown to directly lower cholesterol synthesis.

Descriptor ID	D019161
MeSH Number(s)	D27.505.519.186.071.202.370 D27.505.519.389.370 D27.505.954.557.500.202.370
Concept/Terms	Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl-CoA Reductase Inhibitors Hydroxymethylglutaryl CoA Reductase Inhibitors Inhibitors, Hydroxymethylglutaryl-CoA Reductase Reductase Inhibitors, Hydroxymethylglutaryl-CoA Inhibitors, HMG-CoA Reductase Inhibitors, HMG CoA Reductase Reductase Inhibitors, HMG-CoA HMG-CoA Reductase Inhibitors HMG CoA Reductase Inhibitors Statins, HMG-CoA HMG-CoA Statins Statins, HMG CoA Inhibitors, Hydroxymethylglutaryl-CoA Hydroxymethylglutaryl-CoA Inhibitors Inhibitors, Hydroxymethylglutaryl CoA Statins Inhibitors, Hydroxymethylglutaryl-Coenzyme A Hydroxymethylglutaryl-Coenzyme A Inhibitors Inhibitors, Hydroxymethylglutaryl Coenzyme A

Below are MeSH descriptors whose meaning is more general than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Chemicals and Drugs [D]
Chemical Actions and Uses [D27]
Pharmacologic Actions [D27.505]
Molecular Mechanisms of Pharmacological Action [D27.505.519]
Antimetabolites [D27.505.519.186]
Hypolipidemic Agents [D27.505.519.186.071]
Anticholesteremic Agents [D27.505.519.186.071.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.186.071.202.370]
Enzyme Inhibitors [D27.505.519.389]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.519.389.370]
Therapeutic Uses [D27.505.954]
Lipid Regulating Agents [D27.505.954.557]
Hypolipidemic Agents [D27.505.954.557.500]
Anticholesteremic Agents [D27.505.954.557.500.202]
Hydroxymethylglutaryl-CoA Reductase Inhibitors [D27.505.954.557.500.202.370]

Below are MeSH descriptors whose meaning is related to "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

Below are MeSH descriptors whose meaning is more specific than "Hydroxymethylglutaryl-CoA Reductase Inhibitors".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in this website by year, and whether "Hydroxymethylglutaryl-CoA Reductase Inhibitors" was a major or minor topic of these publications.

Bar chart showing 63 publications over 20 distinct years, with a maximum of 6 publications in 2008

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2003	1	0	1
2004	0	1	1
2005	2	3	5
2006	4	0	4
2007	3	1	4
2008	4	2	6
2009	4	0	4
2010	1	2	3
2011	1	0	1
2012	2	2	4
2013	3	2	5
2014	4	1	5
2015	1	0	1
2016	3	1	4
2017	3	0	3
2018	2	1	3
2019	2	0	2
2020	1	1	2
2021	2	0	2
2023	3	0	3

Below are the most recent publications written about "Hydroxymethylglutaryl-CoA Reductase Inhibitors" by people in Profiles.

Alrajeh K, AlAzzeh O, Roman Y. The frequency of major ABCG2, SLCO1B1 and CYP2C9 variants in Asian, Native Hawaiian and Pacific Islander women subgroups: implications for personalized statins dosing. Pharmacogenomics. 2023 05; 24(7):381-398.

View in: PubMed
AlAzzeh O, Roman YM. The frequency of rs2231142 in ABCG2 among Native Hawaiian and Pacific Islander subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics. 2023 02; 24(3):173-182.

View in: PubMed
Alrajeh K, Roman YM. The frequency of rs2231142 in ABCG2?among Asian subgroups: implications for personalized rosuvastatin dosing. Pharmacogenomics. 2023 01; 24(1):15-26.

View in: PubMed
Watanabe LM, Navarro AM, Seale LA. Intersection between Obesity, Dietary Selenium, and Statin Therapy in Brazil. Nutrients. 2021 Jun 12; 13(6).

View in: PubMed
Alsuhibani A, Albogami Y, Diaby V, Friedman J, Vouri SM. Evaluation of statin discontinuation stratified by primary versus secondary prevention following bariatric surgery: a retrospective cohort study. Surg Obes Relat Dis. 2021 May; 17(5):939-946.

View in: PubMed
Spahillari A, Zhu J, Ferket BS, Hunink MGM, Carr JJ, Terry JG, Nelson C, Mwasongwe S, Mentz RJ, O'Brien EC, Correa A, Shah RV, Murthy VL, Pandya A. Cost-effectiveness of Contemporary Statin Use Guidelines With or Without Coronary Artery Calcium Assessment in African American Individuals. JAMA Cardiol. 2020 08 01; 5(8):871-880.

View in: PubMed
Gamble-George JC, Longenecker CT, Webel AR, Au DH, Brown AF, Bosworth H, Crothers K, Cunningham WE, Fiscella KA, Hamilton AB, Helfrich CD, Ladapo JA, Luque A, Tobin JN, Wyatt GE. ImPlementation REsearCh to DEvelop Interventions for People Living with HIV (the PRECluDE consortium): Combatting chronic disease comorbidities in HIV populations through implementation research. Prog Cardiovasc Dis. 2020 Mar - Apr; 63(2):79-91.

View in: PubMed
Takada S, Ober AJ, Currier JS, Goldstein NJ, Horwich TB, Mittman BS, Shu SB, Tseng CH, Vijayan T, Wali S, Cunningham WE, Ladapo JA. Reducing cardiovascular risk among people living with HIV: Rationale and design of the INcreasing Statin Prescribing in HIV Behavioral Economics REsearch (INSPIRE) randomized controlled trial. Prog Cardiovasc Dis. 2020 Mar - Apr; 63(2):109-117.

View in: PubMed
Dahl L, Schultz A, McGibbon E, Brownlie J, Cook C, Elbarouni B, Katz A, Nguyen T, Sawatzky JA, Sinclaire M, Throndson K, Prior HJ, Fransoo R. Cardiovascular Medication Use and Long-Term Outcomes of First Nations and Non-First Nations Patients Following Diagnostic Angiography: A Retrospective Cohort Study. J Am Heart Assoc. 2019 08 20; 8(16):e012040.

View in: PubMed
El-Zailik A, Cheung LK, Wang Y, Sherman V, Chow DS. Longitudinal Impacts of Gastric Bypass Surgery on Pharmacodynamics and Pharmacokinetics of Statins. Obes Surg. 2019 08; 29(8):2571-2583.

View in: PubMed

People

Explore

Similar Concepts

Top Journals